XML 32 R11.htm IDEA: XBRL DOCUMENT v3.25.1
RESTRUCTURING
 3 Months Ended
Mar. 31, 2025
Restructuring Charges [Abstract]  
RESTRUCTURING RESTRUCTURING
2023 Restructuring Plan

In 2023, BMS commenced a restructuring plan to accelerate the delivery of medicines to patients by evolving and streamlining its enterprise operating model in key areas, such as R&D, manufacturing, commercial and other functions, to ensure its operating model supports and is appropriately aligned with the Company’s strategy to invest in key priorities. These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery, (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network. In 2025, BMS expanded the scope of activities supporting these key priorities. As a result, total charges for the 2023 Restructuring Plan are expected to be approximately $2.5 billion through 2027, with $1.2 billion incurred to date. The remaining charges consist primarily of employee termination costs and site exit costs, including impairment and accelerated depreciation of property, plant and equipment.

Celgene and Other Acquisition Plans

Restructuring and integration plans were initiated to realize expected cost synergies resulting from cost savings and avoidance from the acquisitions of Celgene (2019), Mirati (2024), RayzeBio (2024) and Karuna (2024). For these plans, the remaining charges of approximately $200 million consist primarily of IT system integration costs, employee termination costs, and to a lesser extent, site exit costs, including impairment and accelerated depreciation of property, plant and equipment.

The following provides the charges related to restructuring initiatives by type of cost:
Three Months Ended March 31,
Dollars in millions20252024
2023 Restructuring Plan$143 $68 
Celgene and Other Acquisition Plans47 244 
Total charges$190 $312 
Employee termination costs$132 $217 
Other termination costs1 3 
Provision for restructuring133 220 
Integration expenses41 71 
Accelerated depreciation15 14 
Asset impairments
8 2 
Other shutdown costs, net
(7)5 
Total charges$190 $312 
Cost of products sold$2 $14 
Selling, general and administrative
1 6 
Research and development21 1 
Other (income)/expense, net166 291 
Total charges$190 $312 
The following summarizes the charges and spending related to restructuring plan activities:
Three Months Ended March 31,
Dollars in millions20252024
Beginning balance $297 $188 
Provision for restructuring133 220 
Payments(145)(97)
Foreign currency translation and other3 (2)
Ending balance$288 $309